Foreign direct investment in Indian pharma sector causing concern

19 April 2018
mergers-acquisitions-big

The spate of mergers and acquisitions (M&As) in the Indian pharma sector continues unabated. As foreign players continue to scout for potential Indian targets to complement their existing offerings and provide a platform for incremental growth, the bogey of drug multinational companies (MNCs) attacking India's ability to produce low-cost quality generic drugs has once again come to the fore, reports The Pharma Letter’s India correspondent.

As domestic private equity major ChrysCapital is set to pick up a 10% stake in Mankind Pharmaceuticals, with GIC of Singapore and CPPIB of Canada, for $350 million, the UK’s AstraZeneca has announced its plans to invest $90 million in India over the next five years.

Fosun International, the Chinese conglomerate known to be aggressive on the international M&A circuit, is the latest entrant to join a bidding war to take control of India's second largest healthcare provider, Fortis Healthcare.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical